Oklo plans isotope facility under US Launch Pad initiative

Oklo, a US advanced reactor developer, is advancing plans for Groves-2 Forge, a pilot isotope production facility in Texas. The company's Groves Isotope Test Reactor reached criticality in August 2026 after less than a year of construction. Groves-2 Forge will combine reactor irradiation with downstream processing to produce medical isotopes, starting with lutetium-177 for cancer treatment. The facility is one of twelve projects selected for the Department of Energy's Nuclear Energy Launch Pad initiative, which streamlines the pathway for advanced reactor and fuel-cycle development.

Where this fits

This is a working proof that firm nuclear capacity can be built at pace under a streamlined regulatory pathway. The US has removed the licensing bottleneck that stalls projects for a decade; Oklo built a reactor in under a year. The development also sits outside the renewables-plus-gas model: it produces both firm baseload power and high-value medical isotopes in an integrated facility, solving for reliability and commercial viability at once. Australia has no equivalent regulatory pathway and no isotope production capability; both are now strategic gaps.

What it means

The US and allies are building energy sovereignty in firm power while Australia remains locked into weather-dependent generation. Oklo's speed demonstrates what regulatory clarity unlocks. Australia has banned new nuclear generation, leaving the country dependent on imported battery chemistry, solar panels, and grid services sourced from China's coal-powered supply chain. The medical isotope production is secondary; the signal is that nuclear can move fast when politics allow it.